2025 Expert Speaker Faculty

Artavazd Arumov

Principal

Qiming Venture Partners

Bin Wu

Founder & Chief Executive Officer

Cytodigm, Inc.

CΓ©cile Bauche

Founder & Chief Scientific Officer

Alaya.bio

Dana Foss

Chief Executive Officer & Co-Founder

Editpep

Daniel Getts

Chief Executive Officer

Myeloid Therapeutics

Delai Chen

Director, Nanoparticle Formulation

Beam Therapeutics Inc.

Dhaval Patel

Executive Vice President & Chief Scientific Officer

Sana Biotechnology

Eric Kmiec

Founder, Chief Executive & Scientific Officer

CorriXR Therapeutics

Gilmore O’Neill

President & Chief Executive Officer

Editas Medicine

Gregory Frost

Chairman & Chief Executive Officer

Exuma Biotechnology

John Rossi, VP & Head of Translational Medicine at Capstan Therapeutics

John Rossi

Vice President & Head of Translational Medicine

Capstan Therapeutics

Laura Green

Director, Program Management

Umoja Biopharma

Hear from Lee Cooper, Managing Director at Delos Capital at this year's In Vivo Cell Engineering & Gene Editing Summit

Lee Cooper

Managing Director

Delos Capital

Maurits Geerlings

Co-Founder, President & Chief Executive Officer

NanoCell Therapeutics

Paul Chen

Principal Scientist, Research

Abbvie

Robert Hofmeister

Chief Scientific Officer

Myeloid Therapeutics

Robert Peters

Chief Scientific Officer

Ensoma

Safi Shahda

Executive Medical Director

Intellia Therapeutics

Hear from Tayo Sanders, Chief Business Officer, at Singular Immune at the In Vivo Cell Engineering & Gene Editing Summit.

Tayo Sanders

Chief Business Officer

Singular Immune

Tian Zhu

Chief Executive Officer & Co-Founder

GenEditBio

Xavier Duportet

Co-Founder & Chief Executive Officer

Eligo Bioscience

See Who Else is Attending

What Our Speaker Faculty Has To Say

β€˜I am thrilled to return to the 4th In Vivo Cell Engineering & Gene Summit, as last year's event provided invaluable insights into the latest advancements in in vivo cell and gene therapy and collaborative opportunities. I look forward to deepening my understanding of innovative techniques in gene editing and in vivo engineering this year.’

Bin Wu, Founder & Chief Executive Officer, Cytodigm

What Our Speaker Faculty Has To Say

β€˜As the field of cell & gene therapy rapidly evolves, this conference is an excellent venue to stay abreast of the latest developments’

Maurits Geerlings, Co-Founder, President, Chief Executive Officer, NanoCell Therapeutics
2025 Agenda
Register
Become a Partner